Chemotherapy combined with surgery for recurrent non-small cell lung cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to evaluate the effectiveness of various chemotherapeutic agents, including cisplatin, carboplatin, docetaxel, and gemcitabine, in patients with recurrent non-small cell lung cancer (NSCLC) who have previously undergone surgery. It is a Phase I, open-label, multicenter trial that explores both single-agent and combination therapies to determine their safety and efficacy. The study will assess outcomes such as overall survival, disease-free survival, and metastasis-free survival over a five-year period. The trial includes multiple cohorts to better understand the potential benefits of these treatment strategies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≤ 75 years with histologically proven NSCLC
* No severe major organ dysfunction
* WHO performance status of 0 or 1
* No prior cancer chemotherapy
* A Clinical Stage ≥ IA (T1a, N0, M0) of lung disease but without diagnosed distant metastasis (according to the 1997 revision of the International Union Against Cancer TNM staging system) as determined by a preoperative evaluation that included a pleural computed tomography (CT) scan.

Exclusion Criteria:

* Age ≥ 76
* Severe major organ dysfunction
* WHO performance status of \>1
* Prior cancer chemotherapy
* Stage IV

Where it's running

• China-Japan Union Hospital, Jilin University
  Changchun, Jilin, China Recruiting
• Shanghai 10th People's Hospital
  Shanghai, China Recruiting
• Shanghai Pulmonary Hospital, Tongji University School of Medicine
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Yu Sun, Ph.D — Shanghai Jiao Tong University School of Medicine
• Study coordinator: Yu Sun, Ph.D
• Email: sunyu@sibs.ac.cn
• Phone: 86-21-54923302

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using enhanced immune cells to treat specific types of lung cancer

  This study is testing a new treatment using special immune cells and a drug to see if it can help people with advanced lung cancer that has certain genetic changes and hasn’t improved with previous treatments.

  Recruiting Phase 1 H. Lee Moffitt Cancer Center and Research Institute · Tampa, Florida · NCT05681780

• First-Line Ipilimumab, Nivolumab, and IL-15 Superagonist in Advanced or Recurrent NSCLC

  A phase Ib/II study tests whether adding nogapendekin alfa inbakicept to nivolumab and ipilimumab helps people with stage IV or recurrent non-small cell lung cancer.

  Recruiting Phase 1/2 Washington University School of Medicine · St Louis, Missouri · NCT07355205

• New treatment for advanced non-small-cell lung cancer using a virus and chemotherapy

  This study is testing a new treatment that combines a special virus and chemotherapy to see if it can help people with advanced lung cancer who haven't responded to previous treatments.

  Recruiting at 15 sites Phase 2 Genelux Corporation · Bullhead City, Arizona and 14 other locations · NCT06463665

• Advanced NSCLC with actionable mutations after targeted therapy and chemo: expanded Lung-MAP treatment

  This phase II trial tests whether sacituzumab govitecan alone, ivonescimab alone, or the combination of both can help people with advanced or recurrent NSCLC that has a targetable genetic change.

  Recruiting at 41 sites Phase 2 SWOG Cancer Research Network · Berkeley, California and 40 other locations · NCT07393555

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• MOv19-BBz CAR T cell treatment for FRa-positive lung cancer

  This trial will test whether a single intrapleural infusion of MOv19-BBz CAR T cells given after lymphodepleting chemotherapy is safe and can help control FRa-positive metastatic or recurrent non-small cell lung cancer with malignant pleural effusion.

  Recruiting Phase 1 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07116057

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.